Kaposi Sarcoma (KS) is type of cancer that originates from cells lining blood vessels and lymph nodes. This cancer mainly occurs in the form of tumors on mucous lined surfaces or also on skin. However, Kaposi Sarcoma might also form in other body parts such as the lungs and digestive tracts. The cancerous cells might form purple, brown, or red patches on skin, which are called lesions.
Get Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3354
How is the global Kaposi Sarcoma market’s vendor landscape?
This market mainly depicts a consolidated competitive landscape, wherein only two players jointly held nearly half of the total market shares in 2015. Johnson & Johnson and Merck & Co. Inc. are these two companies which have dominated the vendor scenario in the global Kaposi Sarcoma market. In spite of this, other players are also expected to experience higher contribution towards betterment of the market in future, especially after patents of key drugs sold by the bigwigs expire.
Most of the competitors have embraced strategies such as collaborations, acquisitions, and partnerships for improving their stance in this market.
Which Factors extensively drive the global Kaposi Sarcoma market?
Organ transplantation procedures have seen a rapid rise in the last few years, and this is a key factor driving the market. This is mainly due to higher chances for cancer to exist among patients who have went through an organ transplantation. Most patients about to go through organ transplantation are given immunosuppressive agents that make their body readily accept the transplantation graft. However, doing this increases the risk of patients to catch the cancer. High incidence of HIV/AIDS especially in emerging economies also is prominent factor driving the global Kaposi Sarcoma market.
What is the most prominent drawback of the global sarcoma market?
Extensively high costs of cancer drugs is a prime restraint affecting the market, which might discourage people from opting for necessary treatment. Price of patented drugs also have skyrocketed, making it difficult for middle-class people to seek out treatment. However, several governmental bodies are putting forth initiatives such as funding and reimbursement programs, which could change the entire picture.